Peptide LibraryVasoactive Intestinal Peptide (VIP) dosage in published studies and labels
These are the doses used for Vasoactive Intestinal Peptide (VIP) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Vasoactive intestinal peptide has no approved dosage in the United States. Its human dosing comes from trials of aviptadil, synthetic VIP, in critical COVID-19: a 12-hour intravenous infusion on three days in a row, rising from 50 to 100 to 150 pmol/kg per hour (600, 1,200 and 1,800 pmol/kg a day). In the largest of these trials, TESICO (n=461), aviptadil did not improve recovery at day 90.
| Human dosing established | Yes |
|---|---|
| Route | Intravenous infusion (trials) |
| Frequency | 12-hour infusion once daily |
| Duration studied | 3 days |
| Titration | Escalating infusion rate across the three days, as set by the trial protocol. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| TESICO (ACTIV-3b) — aviptadil in COVID-19 respiratory failure (2023)Clinical trial · Randomised placebo-controlled trial (NCT04843761) | Hospitalised adults with COVID-19 acute hypoxaemic respiratory failure (n=461 in the aviptadil comparison) | Targets of 600 pmol/kg on day 1, 1,200 pmol/kg on day 2 and 1,800 pmol/kg on day 3 | Intravenous infusion over 12 hours | Once daily | 3 days | No improvement in the day-90 recovery outcome versus placebo (odds ratio 1.11, p=0.54) | Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023. |
| NCT04311697 — intravenous aviptadil for critical COVID-19, results postedClinical trial · Phase 2/3 randomised placebo-controlled trial | Adults with critical COVID-19 respiratory failure at ten US hospitals (n=196 randomised) | Escalating infusion of 50, 100 and 150 pmol/kg per hour | Intravenous infusion | Once daily | 3 days | Primary endpoint (alive and free of respiratory failure at day 60) not met | NCT04311697 — Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure |
Where sources disagree
- The trial doses are weight-based infusions in picomoles under intensive-care monitoring. Subcutaneous or nasal microgram protocols published for research VIP do not come from these trials.
- Neither of the two largest intravenous trials met its primary endpoint. The earlier trial's authors reported a survival benefit in secondary analyses, which the larger TESICO trial did not confirm.